Ann: PTX-200 AML Trial Progresses to Higher Dose, page-22

"Both Breast and Ovarian trials were promising. But, both have been put on hold."

I think ptx100 is the really valuable asset, given that it's targeting indications where there is no drug available or in clinical trials (other than ptx100). That also means an easy path to approval and sales. Also good signs of efficacy so far.

As I said before, similar drugs targeting less have sold for billions.

So better for ptx to put their limited resources into ptx100 (and also omni-car, as that could become a market darling).

cheers